Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 021882

Expand all

EXJADE (DEFERASIROX)
125MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: EXJADE
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 125MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N021882
Product Number: 001
Approval Date: Nov 2, 2005
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXJADE (DEFERASIROX)
250MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: EXJADE
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 250MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N021882
Product Number: 002
Approval Date: Nov 2, 2005
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXJADE (DEFERASIROX)
500MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: EXJADE
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 500MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N021882
Product Number: 003
Approval Date: Nov 2, 2005
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English